Back to search

University of British Columbia

New chelators for radiopharmaceutical chemistry

Abstract

dc:description

This thesis presents studies on a new family of oxine (8-hydroxyquinoline) based acyclic chelators for application to radiometals (e.g., ⁶⁴Cu, ⁶⁷/⁶⁸Ga, ¹¹¹In) in nuclear medicine. Picolinic acid-based chelators (“pa” family) are reported as excellent radiometal chelators by our group’s previous study. Further development leads to the next generation chelators – the “ox” family (8-hydroxyquinoline). H₂hox showed a marked improvement from its “pa” counterpart, H₂dedpa, including an easy preparation, single complex species in a broad pH range (1-11) and high log KML (34.4) and pM (28.3) values. H₂hox showed fast (5 minutes) and quantitative ⁶⁸Ga labelling at room temperature with a concentration as low as 10-⁷ M and obtained a high molar activity. Excellent in vitro and in vivo stability was confirmed with plasma challenge experiments and dynamic PET imaging. The chelation enhanced fluorescence emission property was used directly to investigate the cellular distribution of [Ga(hox)]⁺ and showed the potential for dual channel imaging. Expanding from the lead chelator, H₂CHXhox was then synthesized by incorporating a cyclohexane (CHX) in the backbone to pre-organise the chelator and showed a great improvement on the kinetic inertness and thermodynamic stability. H₂C3hox was prepared by adding one more carbon to the backbone of H₂hox to obtain a 6-membered chelate ring, in order to investigate the preference of ring size on metal ion radii. H₂C3hox showed a decrease in solution stability, thought to be due to adopting a less stable conformation in the 6-membered chelate ring. H₄octox was designed with increased denticity (N₄O₄) vs H₂hox (N₄O₂) for larger metal ions and showed fast and stable chelation with metal ions (Y³⁺, In³⁺, La³⁺, Lu³⁺and Gd³⁺) in solution. Its in vitro stability with In³⁺ and Y³⁺ was proved using plasma and Fe³⁺ challenge experiments, and in vivo stability was confirmed with ¹¹¹In SPECT imaging. The 60-fold fluorescence emission increase when complexed with Y³⁺ can also be applied in probe design or bi-modal imaging. These studies have indicated that the new “ox” family of chelators is an excellent and useful platform in the development of radiometal-based pharmaceuticals.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Chemistry
Grantor dc:publisher
University of British Columbia
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Wang, Xiaozhu

Rights

dc:rights
Statement dc:rights
  • Attribution-NonCommercial-NoDerivatives 4.0 International
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/69977

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Wang, Xiaozhu. New chelators for radiopharmaceutical chemistry. doctoral thesis, University of British Columbia, 2019. http://hdl.handle.net/2429/69977